Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 1

Status

Withdrawn 1Terminated 1Completed 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 2Plasma cell 1

Conditions

Prostatic Neoplasms 2Multiple Myeloma 1

Interventions

Cyclophosphamide 416Radiotherapy 276fludarabine 238Gemcitabine 211Cisplatin 203Nivolumab 184pembrolizumab 183Paclitaxel 176Carboplatin 168Magnetic Resonance Spectroscopy 166fludarabine phosphate 156Irinotecan 135Bevacizumab 133Cytarabine 128Specimen Handling 124Capecitabine 124Temozolomide 123Radiosurgery 118Docetaxel 116Biopsy 116Ipilimumab 113Dexamethasone 113Radiation 111Oxaliplatin 110Fluorouracil 110Rituximab 108Etoposide 108Filgrastim 99Lenalidomide 98Everolimus 96

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × OTHER × tasquinimod × Clear all
NCT04405167 2025-10-07

Tasquinimod for the Treatment of Relapsed or Refractory Myeloma

University of Pennsylvania

Phase 1 Terminated
30 enrolled
Plasma cell

Multiple Myeloma

NCT01513733 2018-09-04

CATCH

Duke University

Phase 1 Completed
25 enrolled
Genitourinary

Prostatic Neoplasms

NCT02396368 2015-11-20

Radium-223

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1 Withdrawn
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡